Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital

Final results from GCIG/ENGOT/AGO-OVAR 12, a randomised placebo-controlled phase III trial of nintedanib combined with chemotherapy for newly diagnosed advanced ovarian cancer

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review


  1. Transcriptome-wide association study reveals candidate causal genes for lung cancer

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Change in mammographic density across birth cohorts of Dutch breast cancer screening participants

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. The real-world outcome of metastatic melanoma: Unknown primary vs. known cutaneous

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Differential effects of corticosteroids and anti-TNF on tumor-specific immune responses: implications for the management of irAEs

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  • AGO Study Group-led GCIG/ENGOT Intergroup Consortium
Vis graf over relationer

AGO-OVAR 12 investigated the effect of adding the oral triple angiokinase inhibitor nintedanib to standard front-line chemotherapy for advanced ovarian cancer. At the primary analysis, nintedanib demonstrated significantly improved progression-free survival (PFS; primary endpoint) compared with placebo. We report final results, including overall survival (OS). Patients with primary debulked International Federation of Gynaecology and Obstetrics (FIGO) stage IIB-IV newly diagnosed ovarian cancer were randomised 2:1 to receive carboplatin (area under the curve 5 or 6) plus paclitaxel (175 mg/m2 ) on day 1 every 3 weeks for six cycles combined with either nintedanib 200 mg or placebo twice daily on days 2-21 every 3 weeks for up to 120 weeks. Between December 2009 and July 2011, 1,366 patients were randomised (911 to nintedanib, 455 to placebo). Disease was considered as high risk (FIGO stage III with >1 cm residuum, or any stage IV) in 39%. At the final analysis, 605 patients (44%) had died. There was no difference in OS (hazard ratio 0.99, 95% confidence interval [CI] 0.83-1.17, p = 0.86; median 62.0 months with nintedanib vs. 62.8 months with placebo). Subgroup analyses according to stratification factors, clinical characteristics and risk status showed no OS difference between treatments. The previously reported PFS improvement seen with nintedanib did not translate into an OS benefit in the nonhigh-risk subgroup. Updated PFS results were consistent with the primary analysis (hazard ratio 0.86, 95% CI 0.75-0.98; p = 0.029) favouring nintedanib. The safety profile was consistent with previous reports.

TidsskriftInternational Journal of Cancer
Udgave nummer2
Sider (fra-til)439-448
Antal sider10
StatusUdgivet - 15 jan. 2020

Bibliografisk note

© 2019 UICC.

ID: 59075866